Fujifilm Diosynth Biotechnologies and Piramal Healthcare UK to jointly develop antibody drug conjugates (ADCs)
Singapore: Fujifilm Diosynth Biotechnologies entered into a strategic alliance with Piramal Healthcare UK, whereby the two parties will offer seamless contract development and manufacture antibody drug conjugates (ADCs). The deal will allow customers to benefit from the experience and assets of both organizations, while simplifying the supply chain and vendor management relationships, leading to shorter time-to-clinic.
For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals. The company recently announced an expansion of its cGMP manufacturing facilities at both its RTP and Billingham sites located in the US and the UK respectively.
Mr Stephen Taylor, commercial VP, Fujifilm Diosynth Biotechnologies, said that, "This strategic alliance with Piramal is an important step for us in bringing a new, high-technology offering to the market place. Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development. Piramal is a recognised world-leader in this area and we are delighted to be partnering with them".
Mr Aidan Walker, president, formulations services, Piramal, said that, "We are delighted to combine with Fujifilm Diosynth Biotechnologies to offer a seamless service to customers for the production of antibody conjugates. Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programmes, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients."
